Stat3 is a vital transcription factor that is activated downstream of the gp130 receptor, primarily via IL-6 signaling in adult liver. A new study demonstrates that Stat3 provides hepatoprotection against Fas-mediated apoptotic liver damage by two mechanisms: direct inactivation of caspases and reduction of reactive oxygen species.
Acute liver failure is caused by a variety of insults, including viral hepatitis, toxic liver damage by poisons or drugs, and ischemia. The liver is the first line of protection against damage by ingested agents, including xenobiotics and drugs. Hepatic injury by these agents frequently results in both hepatic necrosis and apoptosis (1) . It is well known that oxidative damage plays a prominent role in hepatic injury mediated by drugs and poison, whereas viral hepatitis and immune-mediated liver damage are believed to occur largely via activation of the Fas apoptotic death pathway. The link between Fas-mediated damage and the induction of reactive oxygen species (ROS) and oxidative damage has only recently been established (2) (3) (4) (5) (6) .
Growth factors and cytokines, such as HGF and IL-6, promote hepatic survival by stimulating liver regeneration and providing hepatoprotection in a variety of liver-injury models, including Fas-mediated injury, toxic damage caused by hepatotoxins (such as CCL 4 ), and ischemic liver injury (1, (7) (8) (9) (10) (11) . These growth factors provide protection against chronic liver injury that ultimately leads to cirrhosis. Part of this protection is mediated by induction of antiapoptotic proteins that regulate the caspase cascade. In this issue of the JCI, Haga and colleagues demonstrate that signal transducer and activator of transcription-3 (Stat3), a key signaling molecule in pathways regulated by IL-6 and related cytokines, blocks apoptotic injury in two ways: induction of anticaspase regulators; and reduction of oxidative injury via upregulation of an antioxidant protein, . These findings provide new insights into common mechanisms of hepatoprotection in both Fasmediated and toxin-mediated acute liver injury and allow predictions about potential therapeutic interventions that could prove beneficial in a variety of liver insults.
The IL-6 signal transduction pathway in liver injury and regeneration IL-6 is a critical proregenerative factor and acute-phase inducer in the liver that also confers resistance to liver injury by hepatic toxins, ischemia, and Fas ( Figure 1 ). Its effects are mediated almost exclusively on hepatocytes within the liver. Although the source of IL-6 within the liver has not been unequivocally established, studies with bone marrow transplantation provide evidence that hepatic Kupffer cells (liver macrophages) are responsible for production of IL-6 in response to liposaccharide or TNF (13) . Secreted IL-6 acts on neighboring hepatocytes in a paracrine fashion to stimulate liver regeneration and repair. IL-6 bound to the soluble IL-6 receptor signals via gp130 and Janus kinase-1 (JAK-1), leading to activation of the Stat3 transcription factor and the MAPK signal transduction cascade. IL-6 -/-livers induce little Stat3 in response to IL-6 activation during liver regeneration after partial hepatectomy, hepatic injury, or acute-phase
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Figure 1
Model for IL-6/Stat3 signaling pathway. IL-6 binds to its soluble receptor, sIL-6r, which binds to the gp130 receptor, resulting in the activation of Janus kinase (JAK). This leads to activation of the MAPK pathway and activation of Stat3 by tyrosine (Y) phosphorylation. Dimerized Stat3 is able to translocate into the nucleus and activate gene transcription. In the liver, this process promotes liver regeneration, the acute-phase response, and hepatoprotection against Fas and toxic damage. P, phosphate.
induction, suggesting that Stat3 may mediate many of the effects of IL-6 (1, 7-10). Conditional Stat3 knockout mice have been used to show that Stat3 is an important component of the IL-6 response during liver regeneration and the acute-phase response, but Stat3 does not account for all of the effects of IL-6, particularly those that are mediated by MAPK activation (14) . Up to 40% of the immediate-early genes induced during liver regeneration are regulated at least in part by IL-6, and a significant subset of these are also regulated by Stat3.
Modulation of Stat3 levels in liver cells points to its critical role in hepatocyte survival
Stat3 is a vital, ubiquitously expressed protein that is activated by a number of ligands in addition to IL-6 (15, 16 Figure 2) . Whereas IL-6-mediated elevation of antiapoptotic proteins is largely posttranscriptional (9), mRNA for these proteins was elevated in the Stat3-overexpressing livers (12) . This difference could be due to the massive overexpression of Stat3 and the fact that adenovirus infection confers a degree of transcriptional induction not seen in normal mice. This mechanistic evaluation was taken to another level by the demonstration that not only anticaspase agents, but also the antioxidant N-acetyl cysteine, were able to provide some protection against the effect of Stat3 deficiency on Fas-mediated apoptosis (12 (Figure 2 ).
Hepatoprotection by redox-dependent and -independent mechanisms
These findings provide important insights into the hepatoprotective properties of IL-6 and its major antiinjury mediator Stat3 (12) .
Though not yet shown, it is expected that IL-6 induces Ref-1, as IL-6 is the major regulator of Stat3 activation in Fas-and toxin-mediated liver injury. Stat3 has not yet been shown to be hepatoprotective in toxic liver damage, but based on these findings, Stat3 is predicted to be hepatoprotective in liver injury. Toxinmediated liver injury occurs largely through the generation of ROS and direct mitochondrial damage, leading to hepatic necrosis with a lesser degree of apoptosis (1) . The level of oxidants may be so high that glutathione is depleted, thereby precluding the activation of caspases, a glutathione-dependent process. By inducing both antioxidant Ref-1 and caspase inhibitors such as Bcl-2, FLIP, and Bcl-XL, IL-6, Stat3, and similar cytokines are hepatoprotective in a broad spectrum of liver injuries mediated by Fas and liver toxins (22) . Cytokines such as IL-6 also promote liver regeneration, another component of the hepatoprotective mechanism that restores liver mass after necrotic or apoptotic injury has occurred. The link between intracellular signals resulting in mitogenic and antiapoptotic effects of these agents remains to be completely dissected. Inhibition of leukocyte migration into target organs has long been an attractive, though challenging, basis for anti-inflammatory strategies. However, to date, the manipulation of leukocyte rolling along blood vessels has not yielded successful new therapies. An important study (see the related article beginning on page 1008) may now open new avenues in this exciting field of anti-inflammatory therapies by introducing a putative inhibitor of poly-N-acetyllactosamine biosynthesis that affects selectin ligand activity and shows efficacy in a rodent skin inflammation model. Tissue-specific localization of T cells is a requirement for immune surveillance in the skin and in addition plays a pivotal role in the pathogenesis of numerous inflammatory skin disorders. Indeed, the evidence that T cells are crucial factors in mediating psoriasis, allergic contact dermatitis, atopic dermatitis, and cutaneous T cell lymphomas is so strong that these diseases are now considered as T cell-mediated dermatoses (1) . Consequently, insight into mechanisms of T cell recruitment to the skin (and other target organs) may lead to novel anti-inflammatory therapies, and the subject is therefore of particular interest.
Selectin and selectin ligand binding: a bittersweet attraction
Selectin and selectin ligand interactions mediate leukocyte rolling along the endothelium
The multistep cascade of T cell migration has been well described (Figure 1) , and the molecular basis for T cell skin homing has been reviewed recently (2) . The first steps of T cell localization to all tissues include leukocyte tethering and rolling along the vessel wall, which is mediated primarily by interactions between selectin and selectin ligand (3) . A number of studies have demonstrated the pivotal role of E-and P-selectin for leukocyte rolling as well as their overlapping and mutually compensating functions (4). Therefore, it was not surprising that a neutralizing antibody solely against E-selectin was found to be without beneficial effects in a recent clinical trial (5) . Probably for these reasons, the development of a potent, but E-selectin-specific lowmolecular weight antagonist called ESA-2 (6) was stopped. The lesson learned from these findings was that potent and clinically active selectin antagonists have to interfere with at least two of the three selectins (E, P, and L) in order to show in vivo efficacy. Some such antagonists have been reported recently (7) .
